On September 14, 2026, AUROLIFE PHARMA LLC received FDA approval for ANDA 214418, underlining its capacity to expand its generic portfolio and leverage additional market share amid potential generic competition. This clearance positions AUROLIFE to capitalize on projected revenue growth, driven by increased accessibility to essential therapeutic alternatives.